ScreenerHero

ERASErasca Inc. Common Stock

NAS · US · Healthcare · Biotechnology · erasca.com
17.63USD-2.44%Mkt Cap: 6.17B $P/E: —

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap6.17B $
Enterprise Value5.75B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-124.55M $
Revenue/Share—
Last Price17.63 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-28.60
PEG—
EV/EBITDA-38.92
EV/Revenue—
P/S—
P/B14.75
EPS (TTM)-0.90
EPS (Forward)-0.60
52W Range
1.33071% of range24.28
52W High24.28 USD
52W Low1.330 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-38.30%
ROA-31.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.45M $
CapEx (TTM)9.63M $
FCF Margin—
FCF Yield-3.41%
Net Debt-224.02M $
Net Debt/EBITDA1.52
Balance Sheet
Debt/Equity0.14
Current Ratio8.29
Quick Ratio8.08
Book Value/Sh1.158 USD
Cash/Share0.7680 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.50 USD
Upside (mean)+33.3%
Target Range20.00 USD – 30.00 USD
$20.00+33.3% to mean$30.00
# Analysts10
Ownership
Shares Out.349.76M
Float242.90M
Insiders9.48%
Institutions84.96%
Short Interest
Short Ratio6.3d
Short % Float9.56%
Short % Out.8.63%
Shares Short29.95M
Short (prev mo.)32.32M
Technical
SMA 5017.57 (+0.3%)
SMA 20012.01 (+46.8%)
Beta0.65
S&P 52W Chg18.16%
Avg Vol (30d)3.84M
Avg Vol (10d)2.83M
Technical Indicators
RSI (14)46.2
MACD0.0941
MACD Signal0.2607
MACD Hist.-0.1666
BB Upper19.22 USD
BB Middle18.34 USD
BB Lower17.46 USD
BB Width9.63%
ATR (14)1.067 USD
Vol Ratio (20d)0.78x